## CORRECTION

## Open Access

# Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

Franco Locatelli, Gerhard Zugmaier 💿, Noemi Mergen, Peter Bader, Sima Jeha, Paul-Gerhardt Schlegel, Jean-Pierre Bourguin, Rupert Handgretinger, Benoit Brethon, Claudia Rossig and Christiane Chen-Santel

### Correction to: Blood Cancer Journal

https://doi.org/10.1038/s41408-020-00342-x published online 24 July 2020

CR in the first 2 cycles achieved MRD response. The article has now been corrected to state 57/69 (82.6%).

Published online: 01 February 2021

The original version of the article contained an error in Fig. 1b, which showed that 57/69 (78.3%) of patients with

В	n/N		MRD response % (95% CI)
All patients with CR in first 2 cycles	57/69	►	82.6 (66.7-87.3)
Baseline blast category			
<5%	11/11	⊢ <b>—</b>	100 (71.5-100.0)
≥5–50%	33/39	► <b></b>	84.6 (69.5-94.1)
≥50%	13/19	<b>⊢</b>	68.4 (43.4-87.4)
Prior relapses			
0	8/10	<b>_</b>	80 (44.4-97.5)
1	13/17	⊢ <b>∎</b> 1	76.5 (50.1-93.2)
≥2	36/42		85.7 (71.5-94.6)
Prior HSCT			
No	35/41	F	85.4 (70.8-94.4)
Yes	22/28		78.6 (59.0-91.7)
		0 20 40 60 80 100	
		MRD response in first 2 cycles	
		miku response in first z cycles	
Fig. 1			

#### © The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction  $\odot$ in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.